tbuckley/cabot-search huggingface dataset:
Abstract P3-05-07: Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines
Authors: S Caceres, L Pena, G Silvan, MJ Illera, B Monsalve, WA Woodward, J Reuben, JC Illera
Journal: Cancer Research (2017)

Abstract Background: Inflammatory breast carcinoma (IBC) is a special type of breast cancer with a poor survival rate and accounts for 6% of diagnosed breast cancers. The role of androgens on breast cancer is on rise in research, trying to propose anti-androgen therapeutic strategies. The aim of this study was to determine the effects in vivo and in vitro of flutamide (anti-androgen drug) on cell proliferation, tumor progression and steroid production in two cancer IBC triple negative cell lines (SUM-149 and IPC-366, human and canine, respectively). Material and Methods: IPC-366 was cultured in Dulbecco's modified Eagle medium nutrient mixture F-12 Ham (DMEM/F12) and SUM149 was maintained in Ham's F-12 media. Flutamide concentrations added to the culture media were: 5 µm, 10 µm, and 15 µm for 72 hours. Additionally, IPC-366 and SUM149 xenotrasplanted mice were used for in vivo assays with the same flutamide concentrations administrated subcutaneously. Steroid hormones determination in culture media and tumor homogenates (pregnenolone (P5), progesterone (P4), dihydroepiandrostenedione (DHEA), androstenedione (A4), testosterone (T), dihydritestosterone (DHT), 17β-estradiol (E2) and estrone sulphate (SO4E1)) were assayed by EIA previously validated. Immunohistochemical (IHC) analysis of the steroidogenic enzymes CYP11A1, 3β-HSD, CYP19A1, 17β-HSD and 5α-reductase were assayed. Results: Percentage of cell proliferation showed a decrease in all treatments in IPC-366 and SUM149. In vivo tumor progression was reduced in around 65% in IPC-366 and SUM149 xenotrasplanted mice. Regarding hormonal secretion assayed in pellets and homogenates. in treated groups there was an increased in steroid secretion as showed the high levels found in P5, P4 and A4. T and DHT concentrations were higher in treated groups, in contrast to E2 levels that decreased. 17β-HSD and 5α-reductase by IHC showed a high expression in treated groups. Conclusion: IPC-366 and SUM149 treated with flutamide reduced the proliferation of neoplastic cells, reduced tumor progression in xenotrasplanted mice and altered steroid hormone secretion by increasing T production and decreasing in E2 levels. These results open a future approach for IBC and triple negative breast cancer. Citation Format: Caceres S, Pena L, Silvan G, Illera MJ, Monsalve B, Woodward WA, Reuben J, Illera JC. Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-05-07.
A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Authors: Jorge E. Cortes, Florian H. Heidel, Michael Heuser, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos Fernandez, Weidong Wendy Ma, M. Naveed Shaik, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan
Journal: Blood (2016)
Abstract IA01: The proteogenomics of breast cancer patient-derived xenografts
Authors: Matthew J. Ellis
Journal: Clinical Cancer Research (2016)

Abstract Next generation DNA sequencing (NGS) has provided vast quantities of data on the genomic landscape of common solid malignancies yet the discovery yield in terms of new treatment approaches has been modest. At the most fundamental level this is because we still lack a deep understanding of how complex somatic changes in the cancer genome drive the cellular phenotypes associated with cancer lethality. Our recent work in breast cancer has demonstrated that discovery mass spectrometry-based proteomics of genome annotated clinical and PDX samples (“proteogenomics”) elucidates functional consequences of somatic mutations, narrows candidate nominations for driver genes within large deletions and amplified regions, and identifies potential therapeutic targets. The advantages of patient-derived xenografts (PDX) as a source of material for proteogenomics are readily evident. Larger amounts of tumor protein required for mass spectrometry can be obtained, sample ischemia can be controlled and drug perturbation studies to study drug resistance can be easily conducted. However we still have to firmly establish that the proteome of the progenitor human tumor strongly correlates with the proteomic characteristics of the tumor that eventually emerges after engrafting into immunocompromised mice. This is critical as from the genomic perspective, engraftment does represent an evolutionary bottle neck that, at least in some cases, alters tumor clonality. The discovery potential as well as limitations of PDX for the emerging area of proteogenomics will therefore be discussed. Citation Format: Matthew J. Ellis. The proteogenomics of breast cancer patient-derived xenografts. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA01.
Abstract P3-01-01: Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer
Authors: KJ Wernli, L Ichikawa, K Kerlikowske, M Bush, D Johnson, DSM Buist, SD Brandzel, WB DeMartini, L Henderson, L Nekhlyudov, T Onega, B Sprague, DL Miglioretti
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Analysis of predictive factors of radiation induced lung injury in patients treated with chemoradiotherapy with lung cancer.
Authors: Shuiyun Han, Gang Lin, Xiaojiang Sun, Weimin Mao, Yaping Xu
Journal: Journal of Clinical Oncology (2015)

e18514 Background: Dose escalation can improve outcome of treatment and is hindered by dose-limiting radiation induced lung injury(RILI).Our work aimed at searching predictive factors associated with the onset of RILI in patients with lung cancer who receiced chemoradiotherapy. Methods: This analysis included 161 patients with stage Ⅰ-Ⅳ lung cancer treated with chemoradiotherapy.Chemotherapy regimens were used upon histologic types(squmaous cell carcinoma,adenocarcinoma,and SCLC),and Radiotherapy was delivered at 1.8–3.0 Gy fractions once daily to a total of 39–66 Gy (median 60). RILI was scored according to a criterion modified form CTCAE4.0.Greater than or equal to 2 levels of RILI defined as symptomatic RILI was the main observation endpoint. Results: Of total 161 patients between April 2010 and May 2011 was retrospectively eligible with a median follow-up time of 545 days(range:39-1453).Among all the patients,141 cases developed RILI(grade 1:90,;grade 2 = 35,;grade 3 = 15,grade 5 = 1) with a 31.7% incidence of SRILI.Univariate analysis revealed that the predictive factors of SRILI were V5,V20,MLD (p = 0.029,0.048,0.041,respectively),with a trend for histologic types(NSCLC vs SCLC,p = 0.092) as well as radiation technology(IMRT vs 3DCRT,p = 0.095). Multivariate analysis identified an independent risk factors for SRILI:MLD(OR:1.249 95%CI:1.055-1.48,p = 0.01).We found that some radiation induced lung change occurred bilaterally while tumor located unilaterally with a incidence of 22.7% (32/141), and higher level of dosimetric parameters like V5,V20,V30,MLD(P were all less than 0.05) was observed in bilateral injury. Dosimetric Factors extracted from bilateral lung injury including V5,V20,V30,MLD were all sinificantly higher in patients with only grade 1 of RILI but not for grade 2-3.Grades of RILI in ipsilateral lung injury was higher than that in bilateral injury(Mann-whitney U test,z = 8.216,p = 0.000). Conclusions: Mean Lung dose(MLD) is an independent predictive factor for RILI,and additional contralateral out-field injury seems not correlated to risk of highergrade for RILI.
New Insights on How Immune Cells Breach Blood Vessel Walls
Authors: Tracy Hampton
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brain-Derived Neurotrophic Factor in Autism Spectrum Disorder
Authors: Keith Fluegge
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
PP80. CAVEOLIN-1 IMPLICATED AS A PRO-INVASIVE GENE IN HIGH-GRADE GLIOMA CELL MODELS: IMPLEMENTATION OF A 3D SPHEROID MATRIX INVASION ASSAY
Authors: Ms Chiara Moriconi, Dr Valentina Palmieri, Dr Giusy Tornillo, Dr Helen Fillmore, Prof Geoff Pilkington, Prof Mark Gumbleton
Journal: Neuro-Oncology (2017)

INTRODUCTION: The poor prognosis associated with Glioblastoma multiforme (GBM) is multifactorial but includes the capacity of residual tumour cells not removed by surgery and resistant to radio-/chemo-therapy undergoing diffuse invasion into the surrounding brain tissue. Caveolin-1 (Cav-1) is the major structural and functional component of caveolae. In a number of tumour types Cav-1 is recognised to participate in cytoskeletal rearrangement, integrin-mediated adhesion and/or matrix remodelling. We proposed Cav-1 serves to promote invasion of GBM cells. To investigate this we have employed in an in-vitro 3D cellular invasion assay. METHOD: The human GBM cell lines, UP007 and UP029 established from primary cultures of biopsy-derived brain tumours (University of Portsmouth), U-87 MG (ECACC) and U-373 MG (ECACC) were genetically modified to stably knock-out Cav-1 using a Lentiviral Cav-1 shRNA approach; corresponding stably transfected non-target (NT) shRNA cell lines were generated as controls. Neuropheres were formed and embedded within an extracellular matrix (Matrigel™). Over a two-/four-day period (depending on cell line) the migration of cells away from the neurophere core (CORE) was quantified by image capture and processing (Image J) using a custom-developed MatLab script for pixel density analysis indicative of the density of migrating cellular material. RESULTS: Cav-1 knockout resulted in significant (P<0.01) reductions (42–54%) in cell invasion (reduced area of invasion and cell density within this area) of UP007, UP029 and U-87 MG; reductions comparable in magnitude to that of exposure to high concentrations of the Src inhibitor – saracatinib (2 μM). The wild-type and control (NT) U-373 MG showed very little invasive capacity with the corresponding Cav-1 negative cells showing only a consistent trend (P>0.05) towards reduced invasion. Depending upon the cell line the Cav-1 knockdown also resulted in reduced size and cellular density of the neurosphere core (UP007 and UP029) indicative of reduced proliferation and/or cell survival capacity. CONCLUSION: Using an in-vitro 3D cellular invasion assay we have found Cav-1 expression in a series of three GBM cell lines to promote cellular invasion capacity. Ongoing studies are addressing signalling mechanisms and the influence of the microenvironment. ACKNOWLEDGEMENTS: CM and MG acknowledge support from the Cancer Research Wales Ed Evans Scholarship for CM. GP and HF acknowledge support from Brain Tumour Research.
Rapid Engraftment of Neutrophils and Platelets with Mesenchymal Stem Cell Based Cord Blood (CB) Expansion (EXP).
Authors: Marcos de Lima, John D. McMannis, Chitra Hosing, Partow Kebriaei, Simon Robinson, Susan Kelly, Leandro de Padua Silva, Marcelo Fernandez-Vina, Alexandre Chiattone, Doyle Bosque, Gabriela Rondon, Sergio Giralt, Laurence Cooper, Julianne J Chen, Simrit Parmar, Roy Jones, Borje Andersson, Laura Worth, Amin Alousi, Ian K. McNiece, Krishna V. Komanduri, Paul J Simmons, Richard E Champlin, Elizabeth J. Shpall
Journal: Blood (2009)
Ledipasvir–sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial
Authors: Jürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, Chohee Yun, Hadas Dvory-Sobol, Wei Zheng, Diana M Brainard, Patrick Ingiliz, Thomas Lutz, Christoph Boesecke, Mark Nelson
Journal: The Lancet. Gastroenterology & hepatology (2017)
The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.
Authors: Chadi Nabhan, Briseis Aschebrook-Kilfoy, Andrew M. Evens, Brian C-H Chiu, Sonali M. Smith, Tait D. Shanafelt, Neil E. Kay
Journal: Blood (2012)
Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Authors: David Gottlieb, Thérèse Aurran, Constantine S. Tam, Mary Sartor, Rémi Letestu, Dennis Carney, Gavin Cull, Vincent Levy, Veronique Leblond, Marie Christine Bene, Andrew Budniak, Stephen Mulligan, Florence Cymbalista
Journal: Blood (2016)
Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma
Authors: Noopur Raje, Edward Anthony Faber, Paul G. Richardson, Gary J. Schiller, Raymond J. Hohl, Adam D. Cohen, Andres Forero, Susan P. Carpenter, Damien Cronier, Christopher Kaiser, James E. Wooldridge, Kenneth C. Anderson
Journal: Blood (2012)
Abstract P4-02-01: Eribulin induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab
Authors: S Ueda, TS Saeki, H Takeuchi, T Shigekawa, T Yamane, I Kuji, A Osaki
Journal: Cancer Research (2017)

Abstract Purpose: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To understand the mechanism of vascular remodeling of eribulin, we compared optical hemodynamic and blood biomarker changes between eribulin and bevacizumab. Methods: Patients with advanced breast cancer with stage III/IV were eligible for the study. Patients were assigned to receive either eribulin or single-agent bevacizumab. Diffuse optical spectroscopic imaging (DOSI) measured tissue concentrations of oxy-hemoglobin (O2Hb), deoxy-hemoglobin (HHb), total hemoglobin (tHb) and oxygen saturation (SO2) of breast tumors before and day 7 after the first infusion. Peripheral blood samples were obtained from the patients to measure plasma concentration of VEGF, bFGF, FLT-3L, EGF, G-CSF, TNFα, IL1b, IL4, IL6, IL8, IL10, IL12p40, and TGF-β1. Results: Baseline DOSI measurement of all 29 patients (eribulin, n = 14 and bevacizumab, n = 15) revealed significantly higher tumor concentrations of O2Hb, HHb, and tHb than that in the normal breast tissue. Eribulin significantly decreased in HHb concentration and increased SO2 during the observation period. This trend was not observed for bevacizumab. Instead, bevacizumab significantly decreased the concentration of O2Hb and tHb. The blood biomarker study revealed that both eribulin and bevacizumab decreased plasma concentrations of VEGF and bFGF, but only eribulin suppressed the plasma concentration of TGF-β1. Conclusions: Optical imaging technology revealed that eribulin, but not bevacizumab, induced tumor reoxygenation after the start of infusion. Eribulin had a potent anti-angiogenic properties as well as bevacizumab, while suppression of TGF-β1 observed by only eribulin could be associated with remodeling of the microvasculature through suppression of activated stromal cells. Citation Format: Ueda S, Saeki TS, Takeuchi H, Shigekawa T, Yamane T, Kuji I, Osaki A. Eribulin induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-02-01.
Epidermal growth factor receptor (EGFR) inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response
Authors: R. Ommori, K. Park, F. Miyagawa, H. Azukizawa, M. Kanno, H. Asada
Journal: British Journal of Dermatology (2017)

Epidermal growth factor receptor inhibitors (EGFRIs) are a well-established targeted therapy for several cancers. Two categories of EGFRIs are known, EGFR tyrosine kinase inhibitors (EGFR-TKIs) and EGFR monoclonal antibodies (EGFR mAbs). These EGFRIs frequently cause cutaneous adverse effects, such as papulo-pustular eruptions, xerosis and chronic paronychia.

This article is protected by copyright. All rights reserved.
Prostate Cancer, Version 1.2014
Authors: James L Mohler, Philip W Kantoff, Andrew J Armstrong, Robert R Bahnson, Michael Cohen, Anthony Victor D'Amico, James A Eastham, Charles A Enke, Thomas A Farrington, Celestia S Higano, Eric Mark Horwitz, Mark H Kawachi, Michael Kuettel, Richard J Lee, Gary R Macvicar, Arnold W Malcolm, David Miller, Elizabeth R Plimack, Julio M Pow-Sang, Sylvia Richey, Mack Roach, Eric Rohren, Stan Rosenfeld, Eric J Small, Sandy Srinivas, Cy Stein, Seth A Strope, Jonathan Tward, Patrick C Walsh, Dorothy A Shead, Maria Ho
Journal: Journal of the National Comprehensive Cancer Network (2013)

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort
Authors: Guillaume Moulis, Johanne Germain, Thibault Comont, Natacha Brun, Claire Dingremont, Brice Castel, Sophie Arista, Laurent Sailler, Maryse Lapeyre‐Mestre, Odile Beyne‐Rauzy, Bertrand Godeau, Daniel Adoue
Journal: American Journal of Hematology (2017)

Abstract The clinical epidemiology of immune thrombocytopenia (ITP) is not well known in adults. This study was aimed at assessing the clinical epidemiology of incident ITP adults, the factors associated with chronicity and exposure to treatments. This study was conducted in the CARMEN registry, a multicentric prospective cohort aimed at including all newly diagnosed ITP adults in the French Midi‐Pyrénées region, South of France (3 million inhabitants) from June 2013. Descriptive analyses and multivariate logistic regression models were conducted. Out of 121 newly diagnosed ITP until December 2014, 113 patients were followed in the region and gave informed consent. Median age was 65 years. Half of the patients were female, 20.3% had a secondary ITP, 50.4% had a Charlson's score ≥1, median platelet count was 17 × 10 9 /L; 50.9% had bleeding symptoms, including 2 severe gastrointestinal tract and 1 intracranial bleedings; 21.4% had another autoimmune disease and 20.3% experienced an infection within the six weeks before ITP onset. Persistency and chronicity rates were 68.2% and 58.7%, respectively. Antinuclear antibodies were associated with chronicity (OR: 2.89, 95% CI: 1.08‐7.74). Sixty‐eight (60.2%) patients were treated during the week following the diagnosis. Factors associated with the use of intravenous corticosteroids were secondary ITP and high bleeding score. Those associated with the use of intravenous immunoglobulin (IVIg) were a high bleeding score and low platelet count. In conclusion, severe bleeding is rare at ITP onset. Associated autoimmune diseases and recent infections were frequent. Antinuclear antibodies seem predictors of chronicity. Intravenous corticosteroids and IVIg were frequently used.
Tocilizumab-Refractory Cytokine Release Syndrome (CRS) Triggered By Chimeric Antigen Receptor (CAR)-Transduced T Cells May Have Distinct Cytokine Profiles Compared to Typical CRS
Authors: Kazusa Ishii, Haneen Shalabi, Bonnie Yates, Cindy Delbrook, Crystal L. Mackall, Terry J Fry, Nirali N Shah
Journal: Blood (2016)
DEK and WT1 Affect Alternative Splicing of Genes Involved in Hematopoietic Cell Lineage and Resistance to Chemotherapy in Acute Myeloid Leukemia Cells.
Authors: Aminetou Mint Mohamed, Morgan Thenoz, Catherine Koering, Pierre Mallinjoud, Didier Auboeuf, Francoise Solly, Meyling Cheok, Olivier Nibourel, Claude Preudhomme, Eric Wattel, Franck Mortreux
Journal: Blood (2012)